Follow

Herantis Pharma to participate in Inderes Life Science evening

07 December 2022 - 09:00

Herantis Pharma Plc, Press Release, 7 December 2022 at 09:00 A.M. EEST

 

Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that CEO, Antti Vuolanto will participate and give a company presentation at:

 

Inderes Life Science evening

Date: December 13, 2022

Location: Helsinki, Finland

 

 

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: [email protected]

 

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

 

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.

 

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

 

For more information, please visit www.herantis.com

 

Provided by: Cision
Nasdaq First North GM Helsinki (Finland)
Herantis Pharma Oyj
Herantis Pharma is a pharmaceutical drug development company. It focused on developing regenerative medicine for unmet clinical needs. The products of the group are CDNF for Parkinson's disease, Lymfactin for secondary lymphedema, CDNF for Amyotrophic lateral sclerosis and CDNF for other neurodegenerative diseases....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More